Edmolin.com

Informed Today Influential Tomorrow

Medicine

Pharmapack announces 2025 Pharmapack award finalists

Pharmapack Europe has announced the finalists for the Pharmapack Awards 2025.

Winners will be revealed at an exclusive ceremony hosted during the event’s opening evening and will celebrate excellence and innovation across eight dynamic categories.

Pharmapack welcomes over 5,700 industry professionals and nearly 400 exhibitors, and is widely acknowledged as the definitive hub for partnering across packaging and drug delivery, but also a key window in tomorrow’s biggest innovations. The annual awards recognise our industry’s brightest stars – companies, teams, and individuals – that are revolutionising the sector with novel approaches that prioritise sustainability, patient-centricity, and technical advancements.

This year introduces three exciting new categories, reflecting the evolving landscape of the pharmaceutical packaging industry. The Women of the Year Award will honour exceptional contributions from women shaping the future of pharmaceutical packaging. The Future Leader Award will spotlight rising stars and innovators under 35 who are driving transformational change within the industry. Finally, the Packaging Company of the Year will celebrate organisations that have achieved advancements in packaging design, sustainability, and functionality.

Commenting on this year’s finalists, Sherma Ellis Daal, brand director pharma at Informa said: “The 2025 finalists have upheld extraordinary standards, and are a testament to the remarkable talent and ingenuity driving the pharmaceutical packaging industry forward. Their innovations showcase not only groundbreaking delivery solutions but also a commitment to greener, more sustainable designs and technologies that enhance patient adherence, efficacy, and overall even their overall experience. At Pharmapack, we are proud to celebrate these visionaries and changemakers who are shaping a better, more inclusive future for healthcare delivery.”

The full shortlist for the 2025 Pharmapack Awards includes the following categories and nominees:

Delivery and Device Innovation

  • Vita Automatic Resuspension Autoinjector Platform – SMC Pharma Services
  • Credence Isolation Valve Technology – Credence MedSystems
  • Elexy Electromechanical Autoinjector – SHL Medical
  • Capa Valve – Capa Valve

Packaging Innovation

  • Paper Pouch for Pharma and Healthcare – Faller Packaging
  • Solutum Technologies – Solutum
  • CereScreen Digital Display Label – Smurfit Westrock
  • Cartonboard Packaging Solution for Medical Implants – Graphic Packaging International
  • Safepack Extended 2.0 – Körber Pharma Packaging Materials
  • Best Vials for Cell Gene Therapy Products – Mitsubishi Gas Chemical Company

Start-Up Innovation

  • Active Label – Active Label SrL
  • Capa Valve – Capa Valve Ltd
  • OC11 Solutions – ADPT Solutions

Woman of the Year

  • Dr. Shehla Javed Akram – Don Valley Pharmaceuticals
  • Asmita Khanolkar – SMC
  • Carole Grassi-Mircich – SGD Pharma

Eco-Design

  • Diofan Ultra736 – Syensqo
  • Omnilock Ultra PAPER – Huhtamaki
  • Next Gen IV Blister-Free Packaging – Schott Pharma
  • New pack for cimzia 200mg prefilled syringe product for japan – UCB Pharma
  • From rigid packaging to flexible packaging – Rotor Print

Patient-Centric Design

  • New Patient-Centric Pack for BIMZELX 160MG Autoinjector – UCB Pharma
  • OralMist Pro – Dr.Ferrer Biopharma
  • Easy Access to Electronic Patient Information Leaflet – Grünenthal

For the full list of finalists and additional details, please visit Pharmapack Awards.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *

Medicine

GSK’s RSV Vaccine Accepted Under Priority Review in USGSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under priority review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. If approved, GSK’s RSV vaccine would be the first vaccine available to help protect this population. Arexvy is currently approved in the US in adults aged 60 and over for the prevention of lower respiratory tract disease (LRTD) caused by RSV. The application is supported by positive results from a phase III trial [NCT05590403]4 evaluating the immune response and safety of GSK’s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to underlying medical conditions. GSK used a Priority Review Voucher to reduce the US FDA review period of a supplemental Biologics License Application (sBLA) by four months. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is 7 June 2024. The burden of RSV disease in adults is likely to be underestimated due to lack of awareness, a lack of standardised testing, and under-detection in surveillance studies.5 People with underlying medical conditions, such as chronic obstructive pulmonary disease (COPD), asthma, chronic heart failure6 and diabetes,7 are at increased risk for RSV disease. RSV can exacerbate these conditions and lead to pneumonia, hospitalisation, or death.8